Edema News and Research

RSS

Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

New target for pneumonia seems to restore tight barriers and fluid clearance in the lungs

Severe pneumonia causes a buildup of fluid in the lungs that makes the basics of breathing and getting oxygen out to the body difficult to impossible.

25 Jul 2018

FDA approves first drug for treatment of adult AML patients with specific genetic mutation

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation.

20 Jul 2018

Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications

Ferring Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved ZOMACTON for injection in four additional pediatric indications

20 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Study shows link between astronauts' weight and post-flight eye changes

New research suggests that changes in the eye that occur during spaceflight may be related to how much an astronaut weighs. The study is published ahead of print in the American Journal of Physiology--Regulatory, Integrative and Comparative Physiology.

31 May 2018

FDA approves first stand-alone prosthetic iris in the U.S.

The U.S. Food and Drug Administration today approved the first stand-alone prosthetic iris in the United States, a surgically implanted device to treat adults and children whose iris (the colored part of the eye around the pupil) is completely missing or damaged due to a congenital condition called aniridia or other damage to the eye.

30 May 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

PanOptica doses first patient in Phase 1/2 dose-ranging clinical trial of PAN-90806

PanOptica, Inc., a private biopharmaceutical company focused on developing innovative ophthalmology therapies, today announced that the Company has dosed the first patient in a Phase 1/2 dose-ranging clinical trial of PAN-90806, a once-daily topical eye drop formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) for the treatment of neovascular eye diseases.

22 May 2018

FDA approves new drug to treat thrombocytopenia in adults with chronic liver disease

The U.S. Food and Drug Administration today approved Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. This is the first drug approved by the FDA for this use.

22 May 2018

FDA grants approval for two drugs administered together to treat aggressive form of thyroid cancer

The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive).

8 May 2018

Researchers find novel approach for in vivo real-time monitoring of metabolites

Real-time monitoring of the dynamics of endogenous molecules in organisms is an important aspect in the study of diseases.

2 May 2018

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

Teva Pharmaceutical Industries Ltd., today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study of COPAXONE (glatiramer acetate injection) 40 mg/mL administered subcutaneously three-times-a-week for the treatment of relapsing forms of multiple sclerosis (RMS).

28 Apr 2018

New optogenetic tools show promise in treating cardiovascular, neuropsychiatric disorders

You've heard of "nature versus nurture," and philosophers argue about which is more important. But how does this work on the cellular level?

27 Apr 2018

FDA approves marketing of AI device to detect diabetic retinopathy

The U.S. Food and Drug Administration yesterday (11th of April 2018), released a statement approving the marketing of world’s first artificial intelligence using medical device that can detect diabetic retinopathy among diabetic patients.

12 Apr 2018

FDA authorizes marketing of first AI device to detect diabetic retinopathy

The U.S. Food and Drug Administration today permitted marketing of the first medical device to use artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy in adults who have diabetes.

12 Apr 2018

Young athletes commonly have bone marrow edema in lower spine, study shows

New research indicates that young recreational and elite athletes commonly accumulate excess fluid in the bone marrow around the joint that connects the spine with the pelvis.

13 Mar 2018

New guidelines aim to improve quality of high altitude medicine

The aim of these guidelines is to standardize data capture in this area of research and thereby guarantee and indeed improve the quality of clinical research. Scientists from Eurac Research led the evaluation and coordinated the group of experts.

27 Feb 2018

FDA approves new treatment for non-metastatic, castration-resistant prostate cancer

The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer.

15 Feb 2018

Debate sessions at Acute Cardiovascular Care 2018 to focus on treatment for heart attack patients

The optimal treatment for heart attack patients will be debated at Acute Cardiovascular Care 2018. The annual congress of the Acute Cardiovascular Care Association, a registered branch of the European Society of Cardiology, will be held 3 to 5 March at the MiCo Milano Congressi in Milan, Italy.

5 Feb 2018

Edema News and Research

Further Reading

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

New target for pneumonia seems to restore tight barriers and fluid clearance in the lungs

FDA approves first drug for treatment of adult AML patients with specific genetic mutation

Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Study shows link between astronauts' weight and post-flight eye changes

FDA approves first stand-alone prosthetic iris in the U.S.

Celgene to share new and updated data around novel hematological therapies

PanOptica doses first patient in Phase 1/2 dose-ranging clinical trial of PAN-90806

FDA approves new drug to treat thrombocytopenia in adults with chronic liver disease

FDA grants approval for two drugs administered together to treat aggressive form of thyroid cancer

Researchers find novel approach for in vivo real-time monitoring of metabolites

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

New optogenetic tools show promise in treating cardiovascular, neuropsychiatric disorders

FDA approves marketing of AI device to detect diabetic retinopathy

FDA authorizes marketing of first AI device to detect diabetic retinopathy

Young athletes commonly have bone marrow edema in lower spine, study shows

New guidelines aim to improve quality of high altitude medicine

FDA approves new treatment for non-metastatic, castration-resistant prostate cancer

Debate sessions at Acute Cardiovascular Care 2018 to focus on treatment for heart attack patients

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News